Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Imetelstat appears headed for approval after its US adcom turns into a damp squib.

Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.